Clinical trial
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
NCT00003395 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003395 |
|---|---|
| Title | Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer |
| Official title | Dose-Ranging Study of Arsenic Trioxide in Advanced Hematologic Cancers |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | arsenic trioxide |
| Start date | Apr 1, 1998 |
| Primary completion | Mar 1, 2000 |
| Completion | Mar 1, 2000 |
| First posted | Aug 16, 2004 |
| Last update posted | Jun 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: